ELENA ANTONIAZZI

ELENA ANTONIAZZI


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in Genes
Verified
Journal Article
Open access
PDF file
AMAngelo maria Minnella
Angelo maria Minnella
RRRoberta Rissotto
Roberta Rissotto
EAELENA ANTONIAZZI
ELENA ANTONIAZZI
MGMarco Di Girolamo
Marco Di Girolamo
Marco LuigettiMarco Luigetti
Marco Luigetti
LOLaura Obici
Laura Obici
The term amyloidosis describes a group of rare diseases caused by protein conformation abnormalities resulting in extracellular deposition and accumulation of insoluble fibrillar aggregates. So far, 36 amyloid precursor proteins have been identified, and each one is responsible for a specific disease entity. Transthyretin amyloidosis (ATTRv) is one of the most common forms of systemic and ocular amyloidosis, due to the deposition of transthyretin (TTR), which is a transport protein mainly synthesized in the liver but also in the retinal pigment epithelial cells. ATTRv amyloidosis may be misdiagnosed with several other conditions, resulting in a significant diagnostic delay. Gelsolin and keratoepithelin are other proteins that, when mutated, are responsible for a systemic amyloid disease with significant ocular manifestations that not infrequently appear before systemic involvement. The main signs of ocular amyloid deposition are in the cornea, irido-corneal angle and vitreous, causing complications related to vasculopathy and neuropathy at the local level. This review aims at describing the main biochemical, histopathological and clinical features of systemic amyloidosis associated with eye involvement, with particular emphasis on the inherited forms. We discuss currently available treatments, focusing on ocular involvement and specific ophthalmologic management and highlighting the importance of a prompt treatment for the potential sight-threatening complications derived from amyloid deposition in ocular tissues.

1 June 2008
Verified
Journal Article
Closed access
EAELENA ANTONIAZZI
ELENA ANTONIAZZI
RGRosanna Guagliano
Rosanna Guagliano
VMV Meroni
V Meroni
SPSara Pezzotta
Sara Pezzotta
PBP E Bianchi
P E Bianchi